1. Introduction
===============

Three major structurally distinct classes of Amaryllidaceae alkaloids are recognized as the lycorane, galanthamine or crinane types ([@bib15]), while several other less common structural variants are also known ([@bib17]). These structural types are related as a consequence of their common biogenesis from the amino acid-derived precursor norbelladine **1** ([Scheme 1](#fig4){ref-type="fig"} ). Representatives from each of the major series include lycorine **2**, galanthamine **3** and crinamine **4**, respectively, illustrating the remarkable structural diversity that Nature has evolved from **1**. The plethora of biological properties exhibited by these compounds is not surprisingly as equally diverse ([@bib2]). Of the galanthamine class, galanthamine **3** itself is the first of the Amaryllidaceae alkaloids to be approved as a pharmaceutical in the treatment of a human disease. Its remarkable ability to reversibly inhibit acetylcholinesterase, of relevance in Alzheimer's and other neuro-degenerative diseases, has very recently led to its approval as a prescription drug under the generic name Reminyl ([@bib11]).Scheme 1Structurally diverse alkaloid representatives of the Amaryllidaceae.

Alkaloids of the crinane series have been shown to exhibit a range of biological activities ([@bib39]). For example, crinamine **4** is known to be cytotoxic to the malarial parasite and to a series of tumor cell lines ([@bib21]), while the activity of 6-hydroxycrinamine against mouse melanoma cells has been documented ([@bib35]) and haemanthamine (the C-3 epimer of crinamine) is known to inhibit protein synthesis and have anti-proliferative action ([@bib14], [@bib10]). We recently demonstrated the potent apoptosis-inducing ability of the α-ethano bridged crinane alkaloids crinamine **4** and the C-3 epimeric haemanthamine. These compounds were shown to be significantly more active than the β-ethano bridged compounds ([@bib31], [@bib34]) demonstrating the critical structural requirements in the vicinity of the C-ring. In the lycorane series, pancratistatin **5**, and its analogues such as narciclasine ([@bib17]), are known for their potent and selective anticancer properties as well as their synthetically challenging structures. Synthetic efforts in this area involving a complementary pair approach and pharmacophore minimization ([@bib28], [@bib29], [@bib30], [@bib32], [@bib33], [@bib36]) disclosed the strict requirements of the free hydroxyl groups in ring-C of the compounds for potent apoptosis-inducing activity. We have shown that pancratistatin induces apoptosis selectively in cancer cells with minimal effect on normal cells and that mitochondria are the site of action ([@bib26]). Evidence for the apoptotic mode of death in cancer cells was related to early activation of caspase-3 followed by flipping of phosphatidyl serine ([@bib16]).

The interesting structural requirements for apoptosis-inducing activity in the pancratistatin-type of lycorane derivative drew our attention to alkaloids of the lycorine subclass. Lycorine **2** is by far the most common alkaloid within the Amaryllidaceae family. This compound exhibits a vast array of biological properties. It is active against poliovirus ([@bib13]), vaccinia smallpox virus ([@bib7]) and SARS-associated coronavirus ([@bib19]). Furthermore, it exhibits antifungal activity against *Saccharomyces cerevisiae* ([@bib6]), is fatal to the protozoan parasite *Trypanosoma brucei* ([@bib25]) and is more potent than indomethacin as an anti-inflammatory agent ([@bib4]). In addition, lycorine **2** has been shown to have insect antifeedant activity ([@bib8]), inhibit ascorbic acid biosynthesis ([@bib1]) and inhibit the enzyme acetylcholinesterase of significance in motor neuron disease ([@bib24]). The fact that it has an inhibitory effect towards cell division and cell elongation in plants suggests that it may inhibit either (or both) RNA and protein synthesis ([@bib5], [@bib14]). As a potential chemotherapeutic, it has shown most promise as an antiproliferative agent of a number of cancer cell lines ([@bib21]). Investigation into the *in vitro* mode of action in a leukemia (HL-60) cell line model established that lycorine **2** suppressed tumor cell growth and reduced cell survival via cell cycle arrest and induction of apoptosis ([@bib22]). Further investigation of the effect of lycorine **2** on severe combined immuno-deficiency (SCID) mice inoculated with HL-60 cells showed that it decreased tumor cell growth and increased survival rates with no observable adverse effects on treated animals ([@bib23]). Arrest of cell cycle progression and apoptosis induction was also the demonstrated mechanism of action of lycorine **2** on multiple myeloma (KM3) cells ([@bib20]).

Motivated by these interesting and diverse biological properties, we decided to investigate structure-activity studies in the lycorine-series in order to further refine some of the pharmacophoric requirements. Herein we describe a concise, chemo- and regioselective three-step synthesis of 1-acetyllycorine **9** from lycorine **2** utilizing the reactivity of the allylic pseudoequatorial C-2 hydroxy group. This selective functionalization allowed us to prepare a mini-library of lycorine derivatives analogues **7--10** ([Scheme 2](#fig5){ref-type="fig"} ). Investigations on the apoptosis-inducing properties of six derivatives showed that only lycorine **2** and pseudolycorine **6** were able to induce apoptosis in human leukemia (Jurkat) cells at the micromolar level.Scheme 2Regio-chemoselective route to 1-acetyllycorine **9**.

2. Results and discussion
=========================

Previous studies have highlighted the difficulties attending the differential functionalization of the hydroxyl groups present within the lycorine series ([@bib38]). Previous work in our group has shown that highly selective mono-silylation of 1,2-diols can be achieved under certain conditions ([@bib27]). The reaction of lycorine **2** with *tert*-butyldimethylsilyl chloride (TBSCl) and pyridine in dichloromethane (DCM) ([Scheme 2](#fig5){ref-type="fig"}) was therefore investigated. To our delight, this reaction afforded the novel monosilyl ether **7** (in 82% yield), most likely due to the greater reactivity of the allylic pseudoequatorial 2-hydroxy group over the axially-orientated C-1 hydroxyl. The ^1^H NMR spectrum of **7** (see Section [3](#sec1){ref-type="sec"}) had the H-2 signal at *δ* 4.29 (dd), upfield-shifted from *δ* 5.37 (dd) where it resonates for lycorine (**2**) while COSY contours were established between H-2 and both H-1 (*δ* 4.43, dd) and H-3 (*δ* 5.42, dd). In addition, three-bond HMBC showed H-2 to be correlated to both C-4 (*δ* 142.01, s) and C-10b (*δ* 41.20, d).

Direct access to **7** allowed us to prepare the new allylic acetate **8**, which was obtained in near quantitative yield from silyl ether **7** upon acetylation with acetic anhydride and pyridine, and its ^1^H NMR spectrum showed the expected deshielding effect on H-1 (*δ* 5.56, dd). Desilylation of **8** proceeded smoothly with tetrabutylammonium fluoride (TBAF) in tetrahydrofuran (THF) to give 1-acetyllycorine **9**, the proton spectrum of which indicated a slight upfield shift for H-2 (*δ* 4.15, dd) compared to **8**, whose spectroscopic data (mpt, α~D~, IR, ^1^H NMR, ^13^C NMR) was similar to literature values (Kobayashi et al., 1984). Acetylation of **9** then provided in 97% isolated yield 1,2-diacetyllycorine **10** which had the H-2 signal at *δ* 5.25 (dd) and its spectroscopic data were in close agreement with documented values (Kobayashi et al., 1984, [@bib3]).

The minipanel of synthetic compounds **7--10** together with natural products lycorine **2** and pseudolycorine **6** were then screened for their ability to induce apoptosis in human leukemia (Jurkat) cells. [Fig. 1](#fig1){ref-type="fig"} depicts the apoptotic index of Jurkat cells treated for 72 h with 1, 5 and 10 μM final concentration of alkaloids **2**,**6** and **7**--**10** respectively. The control cells were treated with vehicle (DMSO) so the final concentrations in the culture media was 0.1, 0.5 and 1%, respectively, to match the volume of vehicle added to treated cells. Generally, mammalian cells tolerate 0.1--0.5% DMSO, but 1% DMSO can show toxicity over 72 h. It is not surprising then, that the 10 μM (10 μL/ml of 1 mm stock solution of compounds) equivalent of vehicle control (1% DMSO) caused an increase in apoptotic cells. The index for lycorine **2** and pseudolycorine **6** is striking with over 85% of cells appearing apoptotic after 72 h treatment at 10 μM. Interestingly, 1-acetyllycorine **9** was apoptotic up to ∼45% at 10 μM while the other analogues (**7**,**8**,**10**) exhibited indices at control levels. Nuclear morphological changes characteristic to apoptosis were visualized by Hoechst staining ([Fig. 2](#fig2){ref-type="fig"}, [Fig. 3](#fig3){ref-type="fig"} ), by which condensed nuclei of cells affected by the treatment are more fluorescent and fragmented in appearance. In parallel with Hoechst staining, cells were also treated with Trypan Blue, to evaluate the extent of necrotic cells, and subjected to Annexin-V binding assays as a further indication of the induction of programmed cell death (data not shown). The mild activity (∼45%) exhibited by 1-acetyllycorine **9** indicates that a small substituent at C-1 is partly tolerated. Overall, it is clear from these results that a free ring-C 1,2-diol is required in the lycorine series (lycorine and pseudolycorine) for potent apoptosis-inducing activity since both the monosubstituted silyl ether **7** as well as disubstituted analogues (**8** and **10**) were all inactive.Fig. 1Apoptotic index in Jurkat cells after 72 h treatment with compounds **2**, **6**, **7**, **8**, **9** and **10**. Data for compounds **2** and **6** at 5 μM concentration, and compounds **2**, **6** and **9** at 10 μM concentration are statistically significant from control values (*p* \> 0.05).Fig. 2Hoechst staining of Jurkat cells treated over 72 h with lycorine and pseudolycorine.Fig. 3Hoechst staining of Jurkat cells treated over 72 h with compounds **7**, **8** and **9**.

In the present study, apoptosis initiation was retained upon replacement of the 8,9-methylenedioxy group in lycorine **2** by 8-methoxy-9-hydroxy substituents in pseudolycorine **6**. This is in contrast to the observation of [@bib37] where substitution of the methylenedioxy group in pancratistatin **5** led to a 10 to 100-fold drop in activity. Intriguingly, the phenanthridine nucleus is common to the crinane, lycorine and pancratistatin series of compounds; with the N to C-10b ethano bridge common to crinane compounds and the N to C-4 ethyl tether characteristic of lycorine compounds.

The present results also draw attention to the subtle, often critical nature of the region around the C-4a, C-10b ring junction. In the crinane alkaloid series, the apoptosis-inducing ability of the α-series far superseded those of the β-series ([@bib31], [@bib34]) in all of the cases examined. The presence of a C-1,C-10b double bond in the pancratistatin series, such as narciclasine, is known to have no detrimental effect on its anticancer activity profile ([@bib36]). We have also demonstrated the mildly modulating influence of the C-1,C-2 double bond in the α-crinane compounds ([@bib31], [@bib34]). The introduction of a *sp* ^2^ hybridized carbon at the ring junction appears to introduce only a minor conformational effect on the pharmacophore. The C-3, C-4 double bond in lycorine **2** may play a similar conformational role to that in the crinane and pancratistatin series since dihydrolycorine derivatives have also been shown to possess activity ([@bib14]).

The overall results ([Fig. 1](#fig1){ref-type="fig"}) superficially appear to be reminiscent of the strict requirement for apoptosis induction in pancratistatin **5**, in which a minimum of three free hydroxyls in ring C is necessary for activity ([@bib30]). However the 1,2-dihydroxy groups present in lycorines **2** and **6**, which we now show to be required for activity, have the opposite absolute configuration to analogous positions as found in pancratistatin. Furthermore, the C-4a and C-10b ring junction in lycorines **2** and **6** is also opposite in configuration to that found in pancratistatin. Given the strict requirements of the ring-C hydroxyl groups that are known for activity in the pancratistatin series, it is remarkable to note that *ent*-pancratistatin derivatives have also been shown to have only slightly reduced anticancer activity ([@bib12]). While removing a single hydroxyl group may result in inactive compounds, changing the absolute configuration of the entire molecule can result in retention of activity. These results demonstrate the importance and high sensitivity of the ring-C region in modulating cytotoxicity and heightens the possibility that all of these compounds (pancratistatin, *ent*-pancratistatin, narciclasine and now also the lycorines), may act upon the same biological receptor.

In conclusion we have demonstrated the selective mono-silylation of the C-2 hydroxyl group in the alkaloid lycorine **2**. This work allowed for the synthesis of a mini-library of differentially functionalized 1,2-diol lycorine derivatives. Biological assaying of these compounds demonstrated that the free 1,2-diol is a pharmacophoric requirement for induction of apoptosis in the lycorine series. Comparisons are drawn between this activity and that demonstrated by the pancratistatin/*ent*-pancratistatin structural types that may indicate a common pharmacophore, drawing attention to the critical nature of the ring-C region (stereochemistry and functionality) and subtleties that are manifest. Further structure-activity studies and biological assays aimed at elucidating the mechanism of action of these derivatives is in progress in our laboratories. Based on the structural similarity of the active compounds to that of pancratistatin, one can hypothesize that these compound could trigger apoptosis by activating Fas-associated Caspase-3, or by destabilizing mitochondria in Jurkat cells as has been previously observed ([@bib9], [@bib26]). A significant amount of work must be done to delineate the biochemical mechanism of induction of apoptosis by these compounds.

3. Experimental {#sec1}
===============

*General:* Melting points (uncorrected) were measured on a Gallenkamp melting point apparatus. Optical rotations were determined on a Perkin--Elmer 241 polarimeter installed with a λ~589~ sodium lamp. IR spectra were measured on a Bio-Rad FTS-40 series spectrometer in dry film. CIMS were run on a Micromass Quattro Ultima spectrometer fitted with a direct injection probe (DIP) with ionization energy set at 70 eV and HRMS (CI) were performed with a Micromass Q-Tof Ultima spectrometer. ^1^H and ^13^C NMR spectra were recorded on a Bruker AV700 spectrometer in CDCl~3~ or CD~3~OD with TMS as internal standard, chemical shifts are reported in units of *δ* (ppm) and coupling constants (*J*) are expressed in Hz. Silica gel Merck (70--230 mesh) was used for CC, silica gel SIL G/UV~254~ for analyt. and SIL G-25/UV~254~ for prep. TLC (both Macherey-Nagel). Spots on chromatograms were detected under UV light (254 nm) and by Dragendorff's reagent stain.

3.1. Extraction and isolation of alkaloids
------------------------------------------

Lycorine **2** and pseudolycorine **6** were obtained from *Narcissus bujei* as previously described by us ([@bib3], [@bib18]) and voucher specimens have been deposited (Herbarium, Institut Botanic, Barcelona, Spain, specimen No. 900191). All alkaloids were single components as indicated by NMR and HPLC analyses.

3.2. Cell Culture
-----------------

Human leukemia (Jurkat) cancer cells were purchased from ATCC, Manassas, VA. Cells were grown and maintained in an incubator set at 37 °C with a 5% CO~2~ atmosphere and 95% relative humidity. RPMI-1640 media (Sigma--Aldrich, Oakville, ON) supplemented with 10% fetal bovine serum (FBS) and 10 μg/mL gentamycin (Life Technologies, Mississauga, ON) was used for cell culture.

3.3. Cell treatment
-------------------

To explore the induction of apoptosis by lycorane alkaloids **2,6,7--10**, Jurkat cells were grown and treated for 24, 48 and 72 h with each alkaloid. Various concentrations of the alkaloids diluted in culture media, from a 10 mM stock in DMSO, ranging from 1 to 20 μM were used and apoptotic induction by alkaloid treatment was calculated. Controls were treated with DMSO (solvent) at concentrations relative to alkaloid treatment.

3.4. Cellular staining
----------------------

Nuclear morphological changes associated with apoptosis were visualized using 10 μM final concentration of cell permeable Hoechst 33342 dye (Molecular Probes, Eugene, OR). Following treatment with various alkaloid concentrations over multiple treatment times, Hoechst 33342 dye was added directly to culture media and allowed to incubate for 10 min at 37 °C. Cells were examined using a fluorescent microscope (Leica DM IRB, Germany); pictures were taken at 40X objective. To obtain an apoptotic index, brightly stained condensed nuclei (apoptotic cells) were counted in a minimum of 5 fields, each containing more than 100 cells, so that a minimum of 500 total cells were counted for each data point. The apoptotic index was created such that apoptotic cells were expressed as a percentage of the total number of cells counted. Statistical analysis was performed using STATISTICA from the data of three separate experiments and p \< 0.05 was obtained for alkaloids **2**,**6**,**7--10**.

3.5. Synthesis
--------------

### 3.5.1. Synthesis of 2-*tert*-butyldimethylsilyloxylycorine **7**

Lycorine **2** (30 mg, 0.105 mmol) was dissolved in 0.315 ml of dry CH~2~Cl~2~ (3 ml/mmol) to which was added dry pyridine (0.025 ml, 0.314 mmol) followed by *tert*-butyldimethylsilyl chloride (16 mg, 0.105 mmol) and the solution stirred at room temperature until TLC (30% EtOAc/hexane) indicated consumption of all starting material (∼6 h). The mixture was then quenched with saturated NH~4~Cl solution (1 ml) and extracted with CH~2~Cl~2~ (5 × 1 ml), the combined organic fractions dried (anhydr. Na~2~SO~4~) and the solvent removed under reduced pressure. The crude gum obtained was subjected to silica gel CC to give **7** as an off-white powder (34.5 mg, 82%). M.p. 130--132 °C. $\lbrack\alpha\rbrack_{\text{D}}^{25}$ −78.1 (*c* 0.1 in CHCl~3~). IR *υ* ~MAX~/cm^−1^ (NaCl): 3610 (OH), 2920, 1605 (Ph), 1506, 1486, 1258 (SiCH~3~), 1110, 1034 (C--O), 932 (OCH~2~O). HRMS (CI): calcd. 402.2101 for C~22~H~31~NO~4~Si, found 402.2108. CIMS 70 eV, *m*/*z* (rel. int.): 402 \[M+1\]^+^ (75), 381 (15), 322 (10), 268 (12), 250 (100), 227 (30), 192 (15), 149 (10), 92 (12). ^1^H NMR (700 MHz, CDCl~3~): *δ* 0.12 (3H, s, Si(C*H* ~3~), 0.15 (3H, s, Si(C*H* ~3~), 0.90 (9H, s, SiC(C*H* ~3~)~3~, 2.34 (1H, ddd, *J*  = 9.1, 8.4, 1.4 Hz, H--12α), 2.61 (2H, m, 2H-11), 2.71 (1H, d, *J*  = 10.5 Hz, H-4a), 2.81 (1H, dd, *J*  = 10.5, 1.4 Hz, H-10b), 3.35 (1H, ddd, *J*  = 9.0, 7.0, 2.1 Hz, H-12β), 3.49 (1H, d, *J*  = 14.0 Hz, H-6α), 4.15 (1H, d, *J*  = 14.0 Hz, H-6β), 4.29 (1H, dd, *J*  = 3.5, 2.8 Hz, H-2), 4.43 (1H, dd, *J*  = 3.5, 1.4 Hz, H-1), 5.42 (1H, dd, *J*  = 2.8, 1.0 Hz, H-3), 5.93 (2H, s, OC*H* ~2~O), 6.60 (1H, s, H-7), 6.84 (1H, s, H-10). ^13^C NMR (176 MHz, CDCl~3~): *δ* 4.58 (q, Si(*C*H~3~), −4.30 (q, Si(*C*H~3~), 18.29 (s, Si*C*(CH~3~)~3~, 25.99 (3q, SiC(*C*H~3~)~3~), 28.73 (t, C-11), 41.20 (d, C-10b), 54.07 (t, C-12), 57.34 (t, C-6), 61.10 (d, C-4a), 72.35 (d, C-2), 72.69 (d, C-1), 101.14 (t, O*C*H~2~O), 104.58 (d, C-10), 107.93 (d, C-7), 118.46 (d, C-3), 127.97 (s, C-6a), 130.66 (s, C-10a), 142.01 (s, C-4), 146.42 (s, C-8), 146.74 (s, C-9).

### 3.5.2. Synthesis of 1-acetyl-2-*tert*-butyldimethylsilyloxylycorine **8**

Silyl ether **7** (25.0 mg, 0.0621 mmol) was dissolved at room temperature in 0.186 ml CH~2~Cl~2~ (3 ml/mmol) to which was added consecutively dry pyridine (0.010 ml, 0.124 mmol) and Ac~2~O (0.010 ml, 0.093 mmol) and the solution stirred for 3 h when TLC (EtOAc/hexane 3:7) indicated the reaction to be complete. The mixture was then diluted with satd. NaHCO~3~ solution (1 ml) and extracted with CH~2~Cl~2~ (5 × 1 ml), the combined organic fractions dried (anhydr. Na~2~SO~4~) and the solvent removed under reduced pressure to yield a gum which was purified on silica gel eluting with (30% EtOAc/hexane) to give compound **8** (26.2 mg, 95%) as a white crystalline powder. M.p. 123--125 °C. $\lbrack\alpha\rbrack_{\text{D}}^{25}$ −58.2 (*c* 0.1 in CHCl~3~). IR *υ* ~MAX~/cm^−1^ (NaCl): 2915, 1720 (CO), 1610 (Ph), 1505, 1485, 1255 (SiCH~3~), 1115, 1032 (C--O), 934 (OCH~2~O). HRMS (CI): calcd. 444.2206 for C~24~H~33~NO~5~Si, found 444.2216. CIMS 70 eV, *m*/*z* (rel. int.): 444 \[M+1\]^+^ (60), 384 (43), 322 (15), 269 (10), 250 (40), 227 (100), 192 (10), 117 (12). ^1^H NMR (700 MHz, CDCl~3~): *δ* 0.11 (3H, s, Si(C*H* ~3~), 0.19 (3H, s, Si(C*H* ~3~), 0.89 (9H, s, SiC(C*H* ~3~)~3~, 1.94 (3H, s, O(CO)C*H* ~3~), 2.38 (1H, ddd, *J*  = 9.1, 8.4, 1.4 Hz, H-12α), 2.63 (2H, m, 2H-11), 2.74 (1H, d, *J*  = 9.8 Hz, H-4a), 2.94 (1H, dd, *J*  = 9.8, 1.4 Hz, H-10b), 3.35 (1H, ddd, *J*  = 9.1, 7.7, 2.1 Hz, H-12β), 3.51 (1H, d, *J*  = 14.0 Hz, H-6α), 4.15 (1H, d, *J*  = 14.0 Hz, H-6β), 4.18 (1H, dd, *J*  = 3.5, 2.1 Hz, H-2), 5.39 (1H, dd, *J*  = 2.1, 1.0 Hz, H-3), 5.56 (1H, dd, *J*  = 3.5, 1.4 Hz, H-1), 5.91 (2H, s, OC*H* ~2~O), 6.57 (1H, s, H-7), 6.73 (1H, s, H-10). ^13^C NMR (176 MHz, CDCl~3~): *δ* 4.59 (q, Si(*C*H~3~), −4.56 (q, Si(*C*H~3~), 18.16 (s, Si*C*(CH~3~)~3~, 21.24 (q, O(CO)*C*H~3~), 25.91 (3q, SiC(*C*H~3~)~3~), 28.71 (t, C-11), 39.47 (d, C-10b), 53.93 (t, C-12), 57.16 (t, C-6), 61.59 (d, C-4a), 69.84 (d, C-2), 72.65 (d, C-1), 101.05 (t, O*C*H~2~O), 105.00 (d, C-10), 107.45 (d, C-7), 118.39 (d, C-3), 127.89 (s, C-6a), 129.66 (s, C-10a), 142.28 (s, C-4), 146.25 (s, C-8), 146.53 (s, C-9), 170.61 (s, O(*C*O)CH~3~).

### 3.5.3. Synthesis of 1-acetyllycorine **9**

Silyl acetate **8** (20 mg, 0.045 mmol) was dissolved at room temperature in 0.225 ml of dry THF (5 ml/mmol) to which was added 1 M tetrabutylammonium fluoride (TBAF) solution (0.0675 ml, 0.0675 mmol) and the solution left stirring until TLC (30% EtOAc/hexane) indicated the reaction to be complete (∼1 h). The mixture was then diluted with satd. NH~4~Cl solution (1 ml) and extracted with EtOAc (5 × 1 ml), the combined organic fractions dried (anhydr. Na~2~SO~4~) and the solvent removed under reduced pressure to yield a gum which was purified on a silica gel column eluted with (EtOAc/hexane; 3:7) to give compound **9** as a light yellow crystalline powder (14.2 mg, 96%). M.p. 218--220 °C. $\lbrack\alpha\rbrack_{\text{D}}^{25}$ −110.5 (*c* 0.5 in CHCl~3~). IR *υ* ~MAX~/cm^−1^ (NaCl): 3605 (OH), 2918, 1725 (CO), 1608 (Ph), 1503, 1482, 1260, 1114, 1035 (C--O), 933 (OCH~2~O). HRMS (CI): calcd. 330.1341 for C~18~H~19~NO~5~, found 330.1328. CIMS 70 eV, *m*/*z* (rel. int.): 330 \[M+1\]^+^ (20), 313 (10), 268 (15), 252 (100), 237 (10), 227 (20), 192 (15), 167 (10), 135 (12), 105 (15). ^1^H NMR (700 MHz, CD~3~OD): *δ* 1.91 (3H, s, O(CO)C*H* ~3~), 2.56 (1H, ddd, *J*  = 9.1, 8.4, 1.4 Hz, H-12α), 2.67 (2H, m, 2H-11), 2.91 (1H, d, *J*  = 9.8 Hz, H-4a), 2.94 (1H, dd, *J*  = 9.8, 1.4 Hz, H-10b), 3.36 (1H, ddd, *J*  = 9.1, 7.7, 2.1 Hz, H-12β), 3.62 (1H, d, *J*  = 14.0 Hz, H-6α), 4.14 (1H, d, *J*  = 14.0 Hz, H-6β), 4.15 (1H, dd, *J*  = 3.5, 2.1 Hz, H-2), 5.57 (1H, dd, *J*  = 3.5, 1.4 Hz, H-1), 5.70 (1H, dd, *J*  = 2.1, 1.0 Hz, H-3), 5.91 (2H, s, OC*H* ~2~O), 6.66 (1H, s, H-7), 6.73 (1H, s, H-10). ^13^C NMR (176 MHz, CD~3~OD): *δ* 20.73 (q, O(CO)*C*H~3~), 29.34 (t, C-11), 40.01 (d, C-10b), 54.64 (t, C-12), 57.42 (t, C-6), 62.89 (d, C-4a), 70.20 (d, C-2), 73.30 (d, C-1), 102.49 (t, O*C*H~2~O), 105.69 (d, C-10), 108.38 (d, C-7), 119.41 (d, C-3), 128.40 (s, C-6a), 130.03 (s, C-10a), 143.32 (s, C-4), 148.04 (s, C-8), 148.29 (s, C-9), 172.00 (s, O(*C*O)CH~3~).

### 3.5.4. Synthesis of 1,2-diacetyllycorine **10**

Hydroxy acetate **9** (9.0 mg, 0.0273 mmol) was dissolved at room temperature in 0.137 ml CH~2~Cl~2~ (5 ml/mmol) to which was added consecutively dry pyridine (0.004 ml, 0.0546 mmol) and Ac~2~O (0.004 ml, 0.00409 mmol) and the solution stirred for 3 h when TLC (EtOAc/hexane; 3:7) indicated the reaction to be complete. The mixture was then diluted with satd. NaHCO~3~ solution (1 ml) and extracted with CH~2~Cl~2~ (5 × 1 ml), the combined organic fractions dried (anhydr. Na~2~SO~4~) and the solvent removed under reduced pressure to yield a gum which was purified on silica gel eluting with EtOAc/hexane (3:7) to give compound **10** (9.8 mg, 97%) as a white crystalline powder. M.p. 210--212 °C. $\lbrack\alpha\rbrack_{\text{D}}^{25}$ −25.2 (*c* 0.9 in CHCl~3~). IR *υ* ~MAX~/cm^−1^ (NaCl): 2915, 1720 (CO), 1605 (Ph), 1500, 1485, 1262, 1115, 1034 (C--O), 932 (OCH~2~O). HRMS (CI): calcd. 372.1447 for C~20~H~21~NO~6~, found 372.1438. CIMS 70 eV, *m*/*z* (rel. int.): 372 \[M+1\]^+^ (100), 357 (10), 341 (12), 329 (14), 311 (60), 250 (80), 222 (15), 165 (10). ^1^H NMR (700 MHz, CDCl~3~): *δ* 1.95 (3H, s, O(CO)C*H* ~3~), 2.08 (3H, s, O(CO)C*H* ~3~), 2.40 (1H, ddd, *J*  = 9.1, 8.4, 1.4 Hz, H-12α), 2.65 (2H, m, 2H-11), 2.77 (1H, d, *J*  = 9.8 Hz, H-4a), 2.88 (1H, dd, *J*  = 9.8, 1.4 Hz, H-10b), 3.37 (1H, ddd, *J*  = 9.1, 7.7, 2.1 Hz, H-12β), 3.53 (1H, d, *J*  = 14.0 Hz, H-6α), 4.15 (1H, d, *J*  = 14.0 Hz, H-6β), 5.25 (1H, dd, *J*  = 3.5, 2.1 Hz, H-2), 5.53 (1H, dd, *J*  = 2.1, 1.0 Hz, H-3), 5.73 (1H, dd, *J*  = 3.5, 1.4 Hz, H-1), 5.92 (2H, s, OC*H* ~2~O), 6.57 (1H, s, H-7), 6.74 (1H, s, H-10). ^13^C NMR (176 MHz, CDCl~3~): 21.09 (q, O(CO)*C*H~3~), 21.29 (q, O(CO)*C*H~3~), 28.83 (t, C-11), 40.67 (d, C-10b), 53.78 (t, C-12), 57.06 (t, C-6), 61.38 (d, C-4a), 69.41 (d, C-1), 71.05 (d, C-2), 101.12 (t, O*C*H~2~O), 105.22 (d, C-10), 107.47 (d, C-7), 113.97 (d, C-3), 126.73 (s, C-6a), 129.58 (s, C-10a), 146.28 (s, C-4), 146.47 (s, C-8), 146.59 (s, C-9), 169.92 (s, O(*C*O)CH~3~), 170.15 (s, O(*C*O)CH~3~).
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